BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Xcell Therapeutics opens an export route for cell therapy culture technology.

In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resemble...

October 29, 2021 | News

Merck Drives New Innovation & Adds Capacity to Advance Next Generation (ADC) Therapies

Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges - New DOLCORE™ platform inc...

October 29, 2021 | News

Hummingbird Bioscience collaborates with Merck for a clinical trial on HMBD-002, our anti-VISTA antibody, in combination with KEYTRUDA®

Under this collaboration, Hummingbird will evaluate the safety, tolerability, and anti-tumor activity of its novel anti-VISTA antibody, HMBD-002, i...

October 26, 2021 | News

BD launches its second center of excellence in flow cytometry for clinical research at CMC In India

The CoE at CMC Vellorewill help to push the bounds of clinical research, provide opportunities for knowledge exchange and conduct diagnosis with highe...

October 25, 2021 | News

PharmAbcine Announces Patent Grant in Australia for Its Anti-VISTA Antibody

The Australian grant represents PMC-309's third global patent approval since it received grants from Russia in June 2021 and South...

October 20, 2021 | News

MYND to Participate in a Monash University (Australia) Proposal for $3 Million Clinical Trial

MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF) is pleased to announce that the Company's pr...

October 18, 2021 | News

Merck and Eisai Receive Positive EU CHMP Opinions

Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Respon...

October 18, 2021 | News

BioAgilytix Closes Acquisition of Australia-based 360biolabs®

360biolabs®, the most comprehensive contract research organization in Australia and New Zealand, has now officially joined forces with BioAgilytix Labs...

October 14, 2021 | News

Fujitsu and University of Tokyo Hospital Embark on Joint Research into AI to Aid the Fight Against Heart Disease

News Facts:- Fujitsu and the University of Tokyo Hospital validate the effectiveness of proprietary AI technology that uses electrocardiographic data...

October 11, 2021 | News

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety D...

September 21, 2021 | News

Jemincare declared Ph I trial of its anti-SARS-CoV-2 neutralizing antibody

The clinical trial of JMB2002 was stated in January 2021. A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phas...

September 14, 2021 | News

HaemaLogiX raises $10 million to advance multiple myeloma treatments

HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor w...

September 09, 2021 | News

Odyssey Group Approved to Start Human Trial to Treat Concussion

The Company’s Clinical Trial Protocol was approved by the Alfred Ethics Committee and allows for the immediate start of the human trial. “We a...

September 08, 2021 | News

Stem Cells for Everyone: I Peace expands its clinical-grade

I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-winning technology of ...

September 08, 2021 | News

Stay Connected